Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.


Journal

Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 06 03 2018
accepted: 20 02 2019
pubmed: 2 3 2019
medline: 1 4 2021
entrez: 2 3 2019
Statut: ppublish

Résumé

Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-2 (MMP-2) and its specific tissue inhibitor (TIMP-2) may play an important role in the pathogenesis of cancer disease. We investigated the plasma levels and diagnostic power (ROC curve analysis) of M-CSF, MMP-2, TIMP-2 and tumor markers CA 125 and SCC-Ag in cervical cancer (CC) patients as compared to control group. The study included 89 patients with cervical cancer. The control group consisted of 50 healthy, untreated women. The plasma levels of M-CSF, MMP-2 and TIMP-2 were determined using ELISA, CA 125 and SCC-Ag - by CMIA method. The median levels of M-CSF, TIMP-2, SCC-Ag and CA 125 in the entire group of CC were significantly different than compared to the healthy women group. MMP-2 showed the highest value of sensitivity from all examined parameters (in stage I of CC - 93.10%, II - 82.76%, III and IV - 96.88%, total group - 92.05%). The highest specificity was obtained by M-CSF (86%). The area under the ROC curve (AUC) of M-CSF (0.8051) was the largest of all the tested parameters (even higher than commonly used tumor markers) in the group of cervical cancer. The combination of M-CSF, MMP-2 or TIMP-2 with SCC antigen resulted in an increase AUCs in all cases (0.8760;0.7880;0.8081;respectively). The findings of this study suggest the usefulness of all examined parameters in the diagnostics of CC patients. Out of the tested substances, M-CSF also appears to be the best candidate for cancer diagnostics in all stages of the disease, based on ROC analysis.

Identifiants

pubmed: 30820752
doi: 10.1007/s12253-019-00626-z
pii: 10.1007/s12253-019-00626-z
pmc: PMC7242253
doi:

Substances chimiques

Biomarkers, Tumor 0
TIMP2 protein, human 0
Tissue Inhibitor of Metalloproteinase-2 127497-59-0
Macrophage Colony-Stimulating Factor 81627-83-0
MMP2 protein, human EC 3.4.24.24
Matrix Metalloproteinase 2 EC 3.4.24.24

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

791-800

Références

Clin Chim Acta. 2006 Sep;371(1-2):112-6
pubmed: 16631152
Int J Gynecol Cancer. 2015 Sep;25(7):1151-64
pubmed: 26207784
Int J Colorectal Dis. 2007 Jan;22(1):33-8
pubmed: 16520929
J Cell Commun Signal. 2012 Jun;6(2):87-95
pubmed: 22227894
Biochimie. 2005 Mar-Apr;87(3-4):287-97
pubmed: 15781315
Pol Merkur Lekarski. 2008 Jul;25(145):38-42
pubmed: 18839612
Cancer Res. 2006 Jan 15;66(2):605-12
pubmed: 16423985
J Gynecol Oncol. 2014 Apr;25(2):124-9
pubmed: 24761216
Ann Lab Med. 2016 May;36(3):223-9
pubmed: 26915610
Front Biosci. 2006 Jan 01;11:479-91
pubmed: 16146745
Folia Histochem Cytobiol. 2012 Jul 04;50(2):213-9
pubmed: 22763962
Biochim Biophys Acta. 2005 May 25;1755(1):37-69
pubmed: 15907591
Int J Biol Markers. 2012 Oct 08;27(3):e186-94
pubmed: 22865301
J Ovarian Res. 2015 May 03;8:27
pubmed: 25935153
Clin Lab. 2016 Sep 1;62(9):1661-1669
pubmed: 28164586
Invasion Metastasis. 1994-1995;14(1-6):234-45
pubmed: 7657516
J Immunol. 2003 Sep 1;171(5):2637-43
pubmed: 12928417
Semin Cancer Biol. 2010 Jun;20(3):161-8
pubmed: 20470890
Growth Factors. 2012 Dec;30(6):357-66
pubmed: 22988839
Growth Factors. 2013 Jun;31(3):98-105
pubmed: 23688065
Angiogenesis. 2014 Jul;17(3):573-85
pubmed: 24197832
J BUON. 2016 Mar-Apr;21(2):320-5
pubmed: 27273940
Clin Cancer Res. 2004 Nov 15;10(22):7621-8
pubmed: 15569994
Mediators Inflamm. 2016;2016:5962946
pubmed: 27445439
Anticancer Res. 2015 Feb;35(2):865-74
pubmed: 25667468
Ann Med. 1999 Feb;31(1):34-45
pubmed: 10219712
Endocr Relat Cancer. 2013 Oct 14;20(6):777-83
pubmed: 24016870
Medicine (Baltimore). 2016 Mar;95(9):e2675
pubmed: 26945355
Przegl Lek. 2007;64(12):987-90
pubmed: 18595499
Biochem Soc Trans. 2016 Apr 15;44(2):333-41
pubmed: 27068937
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Mol Cell Ther. 2014 Jun 03;2:17
pubmed: 26056585
Virol Sin. 2015 Apr;30(2):101-6
pubmed: 25910482
Biochim Biophys Acta. 2010 Jan;1803(1):55-71
pubmed: 20080133
Mol Cell Biochem. 2003 Nov;253(1-2):269-85
pubmed: 14619979
J Cancer Res Clin Oncol. 2014 Sep;140(9):1585-93
pubmed: 24804816
Womens Health Issues. 2016 Sep-Oct;26(5):574-83
pubmed: 27365286

Auteurs

Emilia Lubowicka (E)

Department of Esthetic Medicine, Medical University of Bialystok, Akademicka 3, 15-267, Bialystok, Poland. emila_lubowicka@wp.pl.

Monika Zbucka-Kretowska (M)

Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, 15-276, Bialystok, Poland.

Iwona Sidorkiewicz (I)

Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, 15-276, Bialystok, Poland.

Monika Zajkowska (M)

Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269, Bialystok, Poland.

Ewa Gacuta (E)

Department of Perinatology, Medical University of Bialystok, 15-276, Bialystok, Poland.

Andrzej Puchnarewicz (A)

Department of Urology, Provincial Hospital, 15-278, Bialystok, Poland.

Lech Chrostek (L)

Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269, Bialystok, Poland.

Maciej Szmitkowski (M)

Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269, Bialystok, Poland.

Sławomir Ławicki (S)

Department of Population Medicine and Civilization Diseases Prevention, Medical University of Bialystok, 15-269, Bialystok, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH